With our novel 2D and 3D cell culture media, we made it to the final round of the AC² Innovation Award 2019 for the Aachen region. Our technology based on human blood platelets is one out of five 'technologies of the future' nominated for the award.
"We demonstrate that human platelet lysate (hPL) can replace hS in macrophage cultivation [
The state-of-the-art workshop on the use of human Platelet Lysate for cell therapy was sponsored by PL BioScience. The meeting took place 22‐23 March 2018 in Zurich (Switzerland). Currently, the summarising Committee Report was published. The main stakeholders in the hPL area focused on the question: 'How can hPL further
We wish you a joyful Holiday Season and a happy and successful New Year! We are grateful for the confidence of our customers and partners and look forward to joint projects in 2019.
As one of RWTH Aachen University's Spin-offs, we participated in todays meeting of the science council We are proud to present PL BioScience and our innovative Platelet Lysate-based technologies to the science council. Next to the contact with the members of the council, we enjoyed the exchange
Let's get in touch - at booth no. 4! We are one of the exhibitors at the 6th Annual Conference of the German Stem Cell Network in Heidelberg. Visit us and let's talk about human Platelet Lysate - the ideal cell culture supplement for your adult
19 - 21 September 2018 in Heidelberg - booth no. 4 We participate in the exhibition at the German Cancer Research Center and are looking forward to meeting you at our booth.
New Zealand plans to slaughter 150,000 cows as it tries to eradicate a strain of disease-causing Mycoplasma bovis bacteria. The bacteria was found for the first time in New Zealand in 2017 and can cause cows to develop mastitis, pneumonia, arthritis and other diseases. The impacts on the use and
[embed]https://www.youtube.com/watch?v=STL-rEh9_QQ[/embed] 'What are the remaining challenges in the field of cell culture?' Our CEO Dr. Hatim Hemeda about animal component-free cell culture and market trends. During World Advanced Therapies & Regenerative Medicine Congress 2018 in London, our CEO Hatim spoke to Freya Leask (RegMedNet Editor) about the
22 - 23 March 2018 in Zurich We are proud to be a sponsor of the promising workshop 'Human Platelet Lysate - Current Standards and Future Developments' organised by the Working Party Cellular Therapies of the ISBT. The Workshop aims to provide a forum for manufactures, scientists
PL BioScience is cited on 'LABO ONLINE', the Specialist Portal for analytics, laboratory technology & applications (09 November 2017) (Article only available in German) Textauszüge: "Das humane Blutplättchen-Lysat (hPL) gehört zu den tierserumfreien Nährmedien. [
Interview with our CEO, Dr. Hatim Hemeda, in the Memebers Information Booklet 'Doctors Against Animal Experiments Germany' (Issue 3/2017) (Article only available in German) Textauszug: “Humanes Plattchenlysat ist ein vergleichbar junges Produkt, das erst nach 2013 auf den Markt gekommen ist. […] Es fällt schwer zu glauben, aber
Article in the Memebers Information Booklet 'Doctors Against Animal Experiments Germany' (Issue 3/2017) (Article only available in German) Textauszüge: "Der wichtigste Grund, weshalb auf den Gebrauch von fetalem Kälberserum verzichtet werden sollte, ist, dass die Gewinnung mit erheblichem Leid und dem Tod von Millionen Kälberfeten einhergeht." "Um das millionenfache
PL BioScience is mentioned in the University Newspaper RWTHinsight (Article only available in German) RWTHinsight Issue 01/2016 Photo: Peter Winandy
SEVERIT-Projekt - PL BioScience als Kooperationspartner in einem richtungsweisenden Forschungsvorhaben Die Produktion und Qualitätssicherung von Stammzell-abgeleiteten Extrazellulären Vesikeln für neuartige regenerative und immunmodulierende Therapieansätze sind das Ziel dieses Forschungsvorhabens und wichtige Schritte hin zur klinischen Herstellungserlaubnis. Hierfür kooperieren das Institut für Transfusionsmedizin, die Klinik für Knochenmarktransplantation,
Interview with our colleague Ute Steinbusch in the issue 3/2016 of the magazine 'Laborjournal' (Article only available in German) Textauszug: "Die Zahl serumfreier Alternativen zum FBS steigt. Ein Start-up aus Aachen beispielsweise bietet humanes Blutplättchenlysat (hPL) als Wachstumsmedium an - auf Wunsch sogar dreidimensional. Ein Gespräch über Zweitverwertung und
